Jack Geltosky, Ph.D.
Dr. Geltosky has over 29 years of experience in the pharmaceutical industry, evenly split between R&D and licensing.
Jack is currently the Senior Vice President of Business Development for Arizona Technology Enterprises (AZTE), the technology transfer arm of Arizona State University, a position he has held since 2007.
Boards
Dr. Geltosky served on the Board of Directors of Enzon Pharmaceuticals from 2008-2009 and is currently on the Board of Protox Therapeutics.
Experience
From 2002-2007, Jack was Vice President of External Science, Technology and Licensing at Bristol Myers Squibb. There he was responsible for the acquisition and licensing of compounds, R&D technologies and intellectual property to support the company's drug discovery and development efforts. In this role, Jack and his team identified, evaluated, and co-ordinated due diligence activities on potential in- and out-licensing candidates in pre-clinical and clinical development, across all therapeutic areas. Jack's team consisted of 15 licensing professionals.
Prior to joining BMS, Jack was President and Chief Executive Officer of Message Pharmaceuticals, a privately held biotechnology company focused on the discovery of drugs active on RNA. Previously he worked for SmithKline Beecham as Vice President, Scientific Licensing. He also held several other research and development roles of increasing responsibility with Johnson & Johnson, including Senior Director of Research for the Robert Wood Johnson Pharmaceutical Research Institute. Jack began his career as a research scientist at E.I. DuPont.
Jack holds a B.S. in chemistry from Memphis State University and a Ph.D. in biochemistry from the California Institute of Technology.
Contact
jgeltosky@jsb-partners.com